K. Flaherty

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, The Lancet. Haematology.

Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.

A. Zelenetz, O. Abdel-Wahab, A. Dogan, 2020 .

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, Blood.

Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M

G. Iyer, P. Paik, B. Conley, 2022, European Journal of Cancer.